“Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel hosted by BioPharma Dive.
“Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel hosted by BioPharma Dive.
